Pacira BioSciences, Inc.
PCRX
$24.04
-$0.03-0.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -0.87% | 7.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.87% | 7.21% | |||
| Cost of Revenue | 33.84% | 18.40% | |||
| Gross Profit | -11.77% | 4.12% | |||
| SG&A Expenses | 3.63% | 2.08% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.26% | 6.75% | |||
| Operating Income | 44.02% | 16.70% | |||
| Income Before Tax | 594.24% | -122.13% | |||
| Income Tax Expenses | 40.14% | -25.01% | |||
| Earnings from Continuing Operations | 212.07% | -200.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 212.07% | -200.73% | |||
| EBIT | 44.02% | 16.70% | |||
| EBITDA | -20.88% | 25.73% | |||
| EPS Basic | 215.67% | -202.50% | |||
| Normalized Basic EPS | 1,479.21% | -112.78% | |||
| EPS Diluted | 209.09% | -210.00% | |||
| Normalized Diluted EPS | 1,466.29% | -112.84% | |||
| Average Basic Shares Outstanding | -3.13% | -1.76% | |||
| Average Diluted Shares Outstanding | -2.20% | -2.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||